Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.51 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.46 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21377565 | 0.89 | SIRT2 (0.48) | SIRT2AURKARPS6KB1F2RL3TLR7 | |
| SCHEMBL26326980 | 0.84 | MAPKAPK2 (0.43) | SIRT2AURKARPS6KB1F2RL3MAPKAPK2 | |
| SCHEMBL26326978 | 0.79 | F2RL3 (0.43) | SIRT2AURKARPS6KB1F2RL3MAPKAPK2 | |
| SCHEMBL6079210 | 0.78 | SIRT2 (0.51) | SIRT2AURKARPS6KB1F2RL3SIRT3 | |
| SCHEMBL26508328 | 0.76 | SIRT2 (0.49) | SIRT2AURKARPS6KB1F2RL3SYK | |
| SCHEMBL18213795 | 0.76 | SIRT2 (0.52) | SIRT2AURKARPS6KB1SYK | |
| SCHEMBL14305094 | 0.76 | SIRT2 (0.52) | SIRT2AURKARPS6KB1F2RL3SYK | |
| SCHEMBL13623132 | 0.75 | SIRT2 (0.48) | SIRT2AURKARPS6KB1TLR7SYK | |
| SCHEMBL26508079 | 0.75 | SIRT2 (0.48) | SIRT2AURKARPS6KB1F2RL3 | |
| SCHEMBL28309370 | 0.75 | SIRT2 (0.52) | SIRT2AURKARPS6KB1TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767296-B2 | Heteroaryl compounds as kinase inhibitor | FUJIAN HAIXI PHARMACEUTICALS CO., LTD (CN) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767296-B2 | Heteroaryl compounds as kinase inhibitor | RET, ERBB2, ABL1 | SIRT2 4021/4885AURKA 32/4885RPS6KB1 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.